Antares Pharma (ATRS) Shares Down 5.7%
Antares Pharma Inc (NASDAQ:ATRS)’s share price fell 5.7% during trading on Friday . The company traded as low as $3.11 and last traded at $3.12. 1,277,857 shares traded hands during mid-day trading, an increase of 31% from the average session volume of 976,253 shares. The stock had previously closed at $3.31.
A number of brokerages have commented on ATRS. BidaskClub lowered shares of Antares Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. TheStreet upgraded shares of Antares Pharma from a “d” rating to a “c” rating in a report on Friday, March 1st. Raymond James boosted their price objective on shares of Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a report on Monday, March 4th. Finally, Cowen began coverage on shares of Antares Pharma in a report on Monday, February 25th. They issued an “outperform” rating and a $1.99 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and an average target price of $4.83.
The company has a current ratio of 2.62, a quick ratio of 2.20 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $545.81 million, a P/E ratio of -78.00 and a beta of 1.15.
In other news, Director Jacques Gonella sold 200,000 shares of the business’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $3.65, for a total value of $730,000.00. Following the completion of the sale, the director now owns 9,385,848 shares of the company’s stock, valued at approximately $34,258,345.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.20% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Antares Pharma by 11.6% in the 4th quarter. Geode Capital Management LLC now owns 1,609,722 shares of the specialty pharmaceutical company’s stock worth $4,378,000 after purchasing an additional 167,695 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Antares Pharma during the 4th quarter valued at about $59,000. Millennium Management LLC grew its position in shares of Antares Pharma by 118.2% during the 4th quarter. Millennium Management LLC now owns 1,507,964 shares of the specialty pharmaceutical company’s stock valued at $4,102,000 after buying an additional 816,798 shares during the last quarter. Legal & General Group Plc grew its position in shares of Antares Pharma by 16.6% during the 4th quarter. Legal & General Group Plc now owns 25,244 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 3,587 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its position in shares of Antares Pharma by 359.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $140,000 after buying an additional 40,389 shares during the last quarter. 42.20% of the stock is owned by institutional investors.
Antares Pharma Company Profile (NASDAQ:ATRS)
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: What is a stock buyback?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.